- Home
- GDTC vs SCYX Comparison
GDTC vs SCYX Comparison
Compare GDTC & SCYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GDTC
- SCYX
- Stock Information
- Founded
- GDTC 2018
- SCYX 1999
- Country
- GDTC Singapore
- SCYX United States
- Employees
- GDTC N/A
- SCYX N/A
- Industry
- GDTC Biotechnology: Pharmaceutical Preparations
- SCYX Biotechnology: Pharmaceutical Preparations
- Sector
- GDTC Health Care
- SCYX Health Care
- Exchange
- GDTC Nasdaq
- SCYX Nasdaq
- Market Cap
- GDTC 28.0M
- SCYX 28.5M
- IPO Year
- GDTC 2023
- SCYX 2014
- Fundamental
- Price
- GDTC $2.20
- SCYX $0.70
- Analyst Decision
- GDTC Buy
- SCYX
- Analyst Count
- GDTC 1
- SCYX 0
- Target Price
- GDTC $5.00
- SCYX N/A
- AVG Volume (30 Days)
- GDTC 6.2K
- SCYX 138.2K
- Earning Date
- GDTC 01-01-0001
- SCYX 08-07-2025
- Dividend Yield
- GDTC N/A
- SCYX N/A
- EPS Growth
- GDTC N/A
- SCYX N/A
- EPS
- GDTC N/A
- SCYX N/A
- Revenue
- GDTC $368,838.00
- SCYX $2,630,000.00
- Revenue This Year
- GDTC $5.37
- SCYX $463.61
- Revenue Next Year
- GDTC N/A
- SCYX $310.80
- P/E Ratio
- GDTC N/A
- SCYX N/A
- Revenue Growth
- GDTC N/A
- SCYX N/A
- 52 Week Low
- GDTC $1.20
- SCYX $0.66
- 52 Week High
- GDTC $4.05
- SCYX $2.29
- Technical
- Relative Strength Index (RSI)
- GDTC 52.61
- SCYX 38.69
- Support Level
- GDTC $2.09
- SCYX $0.67
- Resistance Level
- GDTC $2.31
- SCYX $0.75
- Average True Range (ATR)
- GDTC 0.11
- SCYX 0.04
- MACD
- GDTC 0.01
- SCYX 0.00
- Stochastic Oscillator
- GDTC 71.43
- SCYX 33.06
About GDTC CytoMed Therapeutics Limited
CytoMed Therapeutics Ltd is a pre-clinical biopharmaceutical company focused on harnessing its proprietary technologies to create novel cell-based immunotherapies for the treatment of human cancers. The development of its novel technologies has been inspired by the clinical success of existing CAR-T cells in treating hematological malignancies as well as the current clinical limitations and commercial challenges in extrapolating the CAR-T principle into the treatment of solid tumors. Geographically, the company operates in Singapore and Malaysia which is the majority revenue generator.
About SCYX SCYNEXIS Inc.
SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.